Generation of Monoclonal Antibodies against Ag85A Antigen of Mycobacterium tuberculosis and Application in a Competitive ELISA for Serodiagnosis of Bovine Tuberculosis

Zhengzhong Xu1, Ting Hu2, Aihong Xia1, Xin Li2, Ze Liu3, Jingjing Min3, Jingjing He1, Chuang Meng2, Yuelan Yin3, Xiang Chen1* and Xinan Jiao3*

1Jiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, China, 2Key Laboratory of Prevention and Control of Biological Hazard Factors (Animal Origin) for Agrifood Safety and Quality, MOA, Yangzhou University, Yangzhou, China, 3Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou, China

**Correspondence:**
Xiang Chen
chenxiang@yzu.edu.cn;
Xinan Jiao
jiao@yzu.edu.cn

Specialty section:
This article was submitted to Veterinary Infectious Diseases, a section of the journal Frontiers in Veterinary Science

Received: 09 March 2017
Accepted: 20 June 2017
Published: 30 June 2017

INTRODUCTION

Tuberculosis (TB) is an infectious disease that is widely prevalent throughout the entire world. Approximately one-third of the population of the world is infected with Mycobacterium tuberculosis (M. tuberculosis). In 2015, there were an estimated 10.4 million new cases of active TB across the world, and it was responsible for an estimated 1.4 million deaths globally in the same year (1–3).

The majority of secreted proteins found in M. tuberculosis culture filtrate have been shown to be generated by the Ag85 complex, a complex comprised three proteins from a 30- to 32-kDa protein family (Ag85A, Ag85B, and Ag85C). These three proteins are secreted into the culture medium in a 2:3:1 ratio (4, 5). The proteins of the Ag85 complex are encoded by three paralogous genes, fbpA, fbpB, and fbpC, all of which have been shown to be localized to distinct regions of the bacterial genome.
M. tuberculosis Ag85A, Ag85B, and Ag85C are highly homologous on the DNA and amino acid level, with approximately 77% of amino acids shared between Ag85A and Ag85B, and about 71% amino acids shared between Ag85A and Ag85C (6).

The proteins comprising the Ag85 complex have been shown to be abundantly secreted in M. tuberculosis. These proteins play a key role in the final step of cell wall assembly and the maintenance of the bacterial cell envelope integrity by catalyzing the transfer of mycolic acid to the cell wall component, arabinogalactan. In addition, this complex has been shown to play an important role in the synthesis of trehalose dimycolate (TDM), there is great interest in Ag85 as a novel target for drug development (11). The Ag85 complex has been demonstrated to stimulate a strong humoral- and cell-mediated immune response (12). Numerous studies to date have focused on the potential of Ag85 complex in vaccine development, diagnostics, and as a therapeutic drug target (10). Because the Ag85 complex has played a key role in the final step of cell wall assembly and the transfer of mycolic acid to the cell wall component, arabinogalactan. In addition, this complex has been shown to be abundantly secreted in M. tuberculosis, up until this point, there have been no commercial specific mAbs against any Ag85 complex using a novel combination of phage display and yeast display was described (19). And antibodies to Ag85B of M. tuberculosis were produced against Ag85 complex in active TB patients provides further support that the Ag85 complex could also function as a promising diagnostic marker (5, 17).

There were already some works describing the production of monoclonal antibodies (mAbs) to Ag85 complex, nine mAbs were produced against M. tuberculosis Ag85 complex using isoelectric focusing combined with Western blot analysis, the results showed that one antibody was found to be specifically directed only against Ag85B (18). A method to select antibodies against any Ag85 complex using a novel combination of phage and yeast display was described (19). And antibodies to Ag85B of M. tuberculosis were produced and subsequently used to develop ELISA technique for detecting Ag85 in the culture filtrate (20). Up until this point, there have been no commercial specific mAbs available against Ag85A. The widely used anti-Ag85 mAb HYT 27 reacts strongly with M. tuberculosis Ag85C and weaker with Ag85A and Ag85B (21, 22). The rabbit polyclonal antibody against M. tuberculosis Ag85B is only specific for the Ag85B protein (23, 24). Thus, it is necessary to first develop a specific mAb against Ag85A to be used in both basic biological research and Ag85A applicative research.

In this study, we developed mAbs against recombinant Ag85A protein. We showed that all of the generated mAbs exhibit good reactivity with both recombinant Ag85A and endogenous Ag85A via indirect ELISA and Western blot techniques. And mAbs 1C6 and 3B8 were specific only for Ag85A, mAbs 2E6 and 2F2 cross-reacted with Ag85B or Ag85C, while mAb 3D9 react with Ag85A, and 3B8 were specific only for Ag85A, mAbs 2E6 and 2F2 cross-reactivity with both recombinant Ag85A and endogenous Ag85A (6).

mAbs against Ag85A

### MATERIALS AND METHODS

#### Construction of Recombinant Expression Vector

The ftpA gene was PCR amplified from chromosomal DNA isolated from the M. tuberculosis H37Rv strain. The sequences of the primer used for PCR amplification are as follows: sense primer, 5′-TAAATTCCACCATGGTA-3′, antisense primer, 5′-AGTCGATTCATCTGGAGCTAGGCG-3′. Amplification reactions were carried out at 95°C for 5 min followed by 30 cycles at 94°C for 45 s, annealing at 55°C for 1 min, extension at 72°C for 2 min, and final extension at 72°C for 30 min. The generated gene fragments were then ligated to the T-cloning site of a pMD20-T vector (Takara, Japan). This vector was then isolated by digestion with BamHI and EcoRI. The ftpA gene was then ligated into pET-30a and pGEX-6p-1 vectors to generate recombinant plasmids.

The genes ftpA, ftpB, and ftpC were fused genetically to GFP gene to generate GFP-ftpA, GFP-ftpB, and GFP-ftpC fragments, respectively, by the splice overlap extension PCR technique. Briefly, the GFP gene fragment was amplified from the EFGP plasmid by PCR using primers GFP-F1 and GFP-R1. The ftpA, ftpB, and ftpC genes were amplified from the genomic DNA of M. tuberculosis H37Rv strain by PCR, using primers ftpA-F2, ftpA-R2, ftpB-F2, ftpB-R2, ftpC-F2, and ftpC-R2. The sequence for the four pairs of primers was summarized in Table 1. After the first rounds of PCR using GFP-F1/ftpA-R1, ftpA-F2/ftpA-R2, ftpB-F2/ftpB-R2, and ftpC-F2/ftpC-R2, the PCR products were gel purified. In a second round of PCR, using the resulting PCR products as templates, the GFP-ftpA, GFP-ftpB, and GFP-ftpC fusion genes were created by overlap PCR using primers GFP-F1/ftpA-R2, GFP-F1/ftpB-R2, and GFP-F1/ftpC-R2. The sequence GGGGSGGGGS was incorporated at the junction of the GFP fragment and ftpA/ftpB/ftpC gene as a flexible linker. The fusion genes were cloned into the pcDNA3.1(+) vector (Invitrogen, USA) between the EcoRI and XbaI restriction sites to generate pcDNA3.1-GFP-ftpA, pcDNA3.1-GFP-ftpB, and pcDNA3.1-GFP-ftpC constructs and confirmed by restriction endonuclease digestion and DNA sequencing.

| Primers | Sequences |
|---------|-----------|
| GFP-F1  | 5′-TAAATTCCACCATGGTA-3′ |
| GFP-R1  | 5′-TAAATTCCACCATGGTA-3′ |
| ftpA-F2 | 5′-TAAATTCCACCATGGTA-3′ |
| ftpA-R2 | 5′-TAAATTCCACCATGGTA-3′ |
| ftpB-F2 | 5′-TAAATTCCACCATGGTA-3′ |
| ftpB-R2 | 5′-TAAATTCCACCATGGTA-3′ |
| ftpC-F2 | 5′-TAAATTCCACCATGGTA-3′ |
| ftpC-R2 | 5′-TAAATTCCACCATGGTA-3′ |

### TABLE 1 | Primer sequences
Expression and Purification of Recombinant Ag85A Protein
The pET-30a-fbpA and pGEX-6p-1-fbpA constructs were transformed into Escherichia coli strains BL21(DE3) and BL21, respectively. Transformed E. coli cells were cultured and recombinant protein expression was induced using 0.5 mM isopropyl-β-D-thiogalactopyranoside. The cells were then harvested and lysed by sonication on ice. The recombinant proteins, rHis-Ag85A and rGST-Ag85A, were purified from the lysate using the His-binding purification kit (Novagen, Germany) and GST-binding purification kit (GE, USA) according to the manufacturer’s instructions, respectively.

Immunization of Mice and Establishment of Hybridomas
BALB/c mice (females, 6 weeks old) were injected subcutaneously with 80 µg of purified rGST-Ag85A protein mixed with Freund’s complete adjuvant (Sigma-Aldrich, USA) in a 1:1 volumetric ratio. A secondary immunization with the same antigen was also mixed with Freund’s incomplete adjuvant (Sigma-Aldrich, USA) in a 1:1 volumetric ratio, and it was given at 2-week intervals. One week following the secondary immunization, the serum titer was determined using an indirect ELISA method with purified rHis-Ag85A protein. The final booster immunization with the same antigen was injected intravenously 3 days prior to cell fusion, without any adjuvants. Finally, the splenocytes of BALB/c mice were collected and fused with SP2/0 myeloma cells using standard hybridoma methods (25). The mice were housed, handled, and immunized at our animal biosafety facilities, and all procedures were approved by the Institutional Animal Experimental Committee of Yangzhou University. All experiments were performed according to the national guidelines for animal welfare.

Screening of Hybridoma Cells
To screen for positive hybridomas, titers of the hybridoma supernatants were determined using an indirect ELISA method with purified rHis-Ag85A protein. In these experiments, a polyclonal antibody against Ag85A protein was used as positive control, and the supernatant from SP2/0 myeloma cells was used as negative control. After subcloning cells two to three times, hybridoma cells that stably secreted antibody were established. Hybridoma cells were then intraperitoneally injected into BALB/c mice to induce the generation of ascites containing mAbs against Ag85A protein.

Isotype and Titer Analysis
Both the class and subclass of the mAbs against Ag85A produced were determined using a mouse monoclonal antibody isotyping kit (Sigma-Aldrich, USA). Protocols were carried out according to the manufacturer’s instructions.

ELISA plates (Nunc, Denmark) were coated with purified rHis-Ag85A protein (1 µg/ml) and left overnight at 4°C. The next morning, plates were washed three times with PBST and blocked with phosphate-buffered saline (PBS) containing 2% bovine serum albumin (BSA) at 37°C for 2 h. Following the blocking step, the plates were washed three times with PBST. Plates were then incubated with serially diluted culture supernatant and ascites. Plates were incubated with primary antibody for 1 h at 37°C. HRP-conjugated goat anti-mouse IgG antibody (1:8,000 dilution) (Sigma-Aldrich, USA) was then added to each well (100 µl/well) and incubated for 1 h at 37°C. Finally, the TMB substrate was then added to the plates and incubated for 10 min, after which the plates were read at 450 nm.

Western Blot Analysis
Purified rHis-Ag85A, rGST-Ag85A, wtBCG, and rBCG:Ag85A (26) were separated on 12% SDS-PAGE gels. Protein was then transferred to PVDF membrane. The membrane was then blocked for 2 h at room temperature with 2% BSA in PBS. The membrane was then washed three times with PBS containing 0.05% Tween 20 (PBST). Following the washes, the membrane was incubated with anti-Ag85A mAbs (1:1,000) at room temperature for 1 h. The membrane was then washed again three times in PBST, followed by incubation with HRP-conjugated goat anti-mouse secondary antibody (1:2,000) (Sigma-Aldrich, USA). Finally, the membrane was developed using 3,3′-diaminobenzidine tetrahydrochloride (Sigma-Aldrich, USA) and visualized using X-ray film.

Indirect ELISA Assay
ELISA plates (Nunc, Denmark) were coated with MPT63, Rpfe, CFP10-ESAT6, and Ag85A protein (1 µg/ml), respectively, and left overnight at 4°C. The next morning, plates were washed three times with PBST and blocked with PBS containing 2% BSA at 37°C for 2 h. Following the blocking step, the plates were washed three times with PBST. Plates were then incubated with the anti-Ag85A mAbs (1:2,000 dilution). Plates were incubated with primary antibody for 1 h at 37°C. HRP-conjugated goat anti-mouse IgG antibody (1:8,000 dilution) (Sigma-Aldrich, USA) was then added to each well (100 µl/well) and incubated for 1 h at 37°C. Finally, the TMB substrate was then added to the plates and incubated for 10 min, after which the plates were read at 450 nm.

Transient Transfection and Indirect Immunofluorescence Test
One day prior to transfection, HEK293T cells were plated in 24-well plates in complete DMEM at a density of 1 × 10⁴ cells/well. Cells were permitted to attach to the plate overnight at 37°C in a 5% CO₂ atmosphere. The following day, HEK293T monolayers were transfected with the pcDNA3.1-GFP-fbpA, pcDNA3.1-GFP-fbpB, and pcDNA3.1-GFP-fbpC constructs using Lipofectamine reagent 3000 (Invitrogen, USA) according to the manufacturer’s instructions.

Twenty-four hours posttransfection, HEK293T cells were washed twice with PBS. Cells were then fixed with methanol for 15 min at room temperature. Following fixation, the cells were incubated with anti-Ag85A mAbs for 2 h at room temperature. The cells were then washed with PBS and incubated with Alexa Fluor® 586 conjugated goat anti-mouse IgG secondary antibody (Life Technology, USA) for 1 h. Cell staining was observed using fluorescence microscopy.
Detection of Ag85A Protein in BCG and rBCG:Ag85A

ELISA plates (Nunc, Denmark) were first treated with 5% glutaraldehyde (100 µl/well) and incubated at 37°C for 2 h. Plates were then washed three times with PBST. Following the washes, plates were coated with 1 x 10^5 colony-forming units of BCG or rBCG:Ag85A bacteria (100 µl/well) and left overnight at 56°C. The plates were washed with PBST and blocked with PBS containing 2% BSA at 37°C for 1 h. Then, the plates were washed and incubated with the mAbs for 2 h at 37°C. HRP-conjugated goat anti-mouse IgG antibody (1:8,000 dilution) (Sigma-Aldrich, USA) was added to each well (100 µl/well) and incubated for 1 h at 37°C. Finally, the TMB substrate was then added to the plates and incubated for 10 min, after which the plates were read at 450 nm.

Protocol of cELISA Assay

ELISA plates (Nunc, Denmark) were coated with rHis-Ag85A protein (1 µg/ml) overnight at 4°C. The next morning, plates were washed three times with PBST and blocked with PBS containing 2% BSA at 37°C for 2 h. Following the blocking step, the plates were washed three times with PBST. Test and control sera samples were diluted 1:100 in PBS and added to each well (50 µl/well), and HRP-labeled anti-Ag85A antibody 3B8 were diluted (1:1,000) and added to each well (50 µl/well), followed by incubation at 37°C for 2 h and washing. Finally, the TMB substrate was then added to the plates and incubated for 10 min, after which the plates were read at 450 nm. Results were calculated based on the OD450 values of the negative control serum sample (N) and test serum sample (S) using the following formula: % inhibition = [(N - S)/N] x 100%. A total of 200 healthy bovine serum samples were tested for determination of cutoff point. The mean inhibition rate + 3× SD was cutoff point (Cn). If the inhibition rate ≥Cn, the bovine TB antibody reaction is positive, if the inhibition rate <Cn, the bovine TB antibody reaction is negative.

Evaluation of cELISA for Detection of Anti-Ag85A Antibody

Total of 298 serum samples were harvested from dairy farms, of which 76 samples are positive and 228 samples are negative identified by PPD skin test, 70 samples are positive and 228 samples are negative identified by interferon-gamma release assay (IFN-γ assay) (Prionics, Switzerland). Bovine serum samples were diluted 100-fold and the inhibition rate was measured using cELISA method based on the criteria described above to determine the sensitivity and specificity of the assay.

Statistical Analysis

All data are expressed as mean ± SEM. Statistical analysis was performed using a Student's t-test. A value of *P < 0.05, **P < 0.01, ***P < 0.001 was considered statistically significant.

RESULTS

Isotype and Titer Analysis of mAbs

Following two to three rounds of cell subcloning and detection, hybridoma cells producing anti-Ag85A mAbs were established and named 1C6, 2E6, 2F2, 3B8, and 3D9. Isotype analysis of the mAbs produced against Ag85A protein was determined using a mouse mAb isotyping kit. These results demonstrated that all nine mAbs belong to the IgG1 isotype (Table 2). In addition, ELISA results suggested that both hybridoma supernatant and ascites possessed high titer levels (Table 2).

Western Blot Analysis

The reactivity of anti-Ag85A mAbs against recombinant Ag85A protein was studied using Western blot analysis. We show that all anti-Ag85A mAbs react with rHis-Ag85A and rGST-Ag85A protein (Figure 1), with all the mAbs exhibiting good reactivity.

Indirect ELISA Assay

In order to evaluate the specificity of anti-Ag85A mAbs, the cross-reactivity of anti-Ag85A mAbs against other protein from mycobacteria was detected by indirect ELISA assay. The results showed that anti-Ag85A mAbs 1C6, 2E6, 2F2, 3B8, and 3D9 did not react with MTP63, RpfE, and CFP10-ESAT6 (Figure 2). All the mAbs did not react with selected mycobacteria protein, suggesting these mAbs are specific to Ag85A protein.

Indirect Immunofluorescence Test

In order to evaluate the cross-reactivity of anti-Ag85A mAbs with the Ag85 complex, HEK293T cells were transfected with pcDNA3.1- fbpA-GFP, pcDNA3.1- fbpB-GFP, and pcDNA3.1- fbpC-GFP constructs. Cells were then stained with the anti-Ag85A mAbs. We show that following staining with mAbs 1C6 and 3B8, only HEK293T cells transfected with pcDNA3.1- fbpA-GFP exhibited yellow fluorescence (Figures 3A,D). However, HEK293T cells transfected with pcDNA3.1- fbpB-GFP and/or pcDNA3.1- fbpC-GFP also exhibited yellow fluorescence following staining with the mAbs 2E6, 2F2, and 3D9 (Figures 3B,C,E). The HEK293T cells in the control group did not exhibit yellow fluorescence (Figure 3F). This suggests that a subset of anti-Ag85A mAbs cross-react with Ag85B and/or Ag85C. The mAbs 2F2 and 2E6 cross-react with Ag85B and Ag85C, respectively, and the mAbs 3D9 can react with Ag85A, Ag85B, and Ag85C.

Detection of Ag85A Protein in BCG and rBCG:Ag85A

To determine whether the generated mAbs can also combine with endogenous Ag85A protein in BCG, we used Western blot and indirect ELISA methods to detect BCG and rBCG:Ag85A. We showed that all anti-Ag85A mAbs reacted with endogenous Ag85A protein in BCG and rBCG:Ag85A, the 31-kDa Ag85A protein was studied using Western blot analysis. The results showed that anti-Ag85A mAbs 1C6, 2E6, 2F2, 3B8, and 3D9 did not react with MTP63, RpfE, and CFP10-ESAT6 (Figure 2). All the mAbs did not react with selected mycobacteria protein, suggesting these mAbs are specific to Ag85A protein.

| Identification and characteristic of anti-Ag85A monoclonal antibodies (mAbs). |
|-------------------------------|-----------------|-----------------|-----------------|
| mAbs | Isotype | Supernatant titer | Ascites titer |
| 1C6 | IgG1 | 1:81,902 | 1:8,192,000 |
| 2E6 | IgG1 | 1:10,240 | 1:16,384,000 |
| 2F2 | IgG1 | 1:327,680 | 1:16,384,000 |
| 3B8 | IgG1 | 1:20,480 | 1:1,024,000 |
| 3D9 | IgG1 | 1:40,960 | 1:8,192,000 |
Indirect ELISA assay. The specificity of anti-Ag85A monoclonal antibodies (mAbs) was detected by indirect ELISA. All anti-Ag85A mAbs strongly recognized Ag85A protein, but did not react with MPT63, RpfE, and CFP10-ESAT6 protein. The control group was recombinant protein react with SP2/0 ascites. Data depicted are the mean values ± SEM. Statistical significance was determined by a Student’s t-test (\(* P < 0.01, ** P < 0.001\)).

Development of cELISA for Detection of Anti-Ag85A Antibody

A cELISA for detection of anti-Ag85A antibody was established. The rHis-Ag85A protein was coated on the ELISA plate as capture antigen, and anti-Ag85A antibody clone 3B8 was used as a detection antibody. The OD_{450} value was detected for 200 healthy bovine serum samples, the mean inhibition rate was 0.162 with a SD of 0.029, the Cn value was 0.249 (≈25%). A total of 248 serum samples (48 bovine TB positive samples and 200 bovine TB negative samples detected by both skin test and IFN-\(\gamma\) assay) were detected, the inhibition rate of 26 samples were above 25%, and the inhibition rate of 167 samples were below 25%, the results indicated that the diagnostic specificity and sensitivity were 54.2% (26/48) and 83.5% (167/200), respectively. A total of 298 serum samples (76 positive by skin test; 222 negative by skin test) were analyzed, the cELISA results were compared with those of the skin test. 45 skin test positive serum samples were also positive by cELISA, with a positive coincidence of 54.2% (90/166). And 177 skin test negative serum samples were negative by cELISA, with a negative coincidence of 82.3% (354/430). Therefore, the total coincidence of the cELISA method and skin test was 74.5% (Table 3). And the results were also compared with the IFN-\(\gamma\) assay, 298 serum samples (70 positive by IFN-\(\gamma\) assay; 228 negative by IFN-\(\gamma\) assay) were detected, 38 serum samples were also positive by cELISA with a positive coincidence of 47.5% (76/160), and 176 serum samples were also negative by cELISA with a negative coincidence of 80.7% (352/436). Therefore, the total coincidence of the cELISA assay and IFN-\(\gamma\) assay was 71.8% (Table 4).

DISCUSSION

The Ag85A protein is a member of the Ag85 complex, a 30- to 32-kDa family of three proteins (Ag85A, Ag85B, and Ag85C). All three members of the Ag85 complex have been shown to exhibit mycolyltransferase activity (27). Interestingly, Ag85A has also been shown to stimulate production of Th1 cytokines and CTL activity. Because this protein generates a strong immune response, it is thought to be an ideal candidate antigen for the development of novel vaccines (28, 29).

However, there were still no commercial mAbs available against Ag85A. Thus, it may hinder the biological research and applicable research of Ag85A. The widely used commercial anti-Ag85
TABLE 4 | Comparative result of competitive ELISA (cELISA) assay and IFN-γ assay.

| IFN-γ assay | cELISA assay | Total |
|------------|--------------|-------|
|            | P            | N     |       |
| IFN-γ assay| 38           | 32    | 70    |
| Total      | 90           | 208   | 298   |

TABLE 3 | Comparative result of competitive ELISA (cELISA) assay and skin test.

| skin test | cELISA assay | Total |
|-----------|--------------|-------|
|           | P            | N     |       |
| Skin test | 45           | 31    | 76    |
| N          | 45           | 177   | 222   |
| Total      | 90           | 208   | 298   |

FIGURE 3 | Indirect immunofluorescence test. HEK293T cells transfected with pcDNA3.1-ftbpA-GFP, pcDNA3.1-ftbpB-GFP, and pcDNA3.1-ftbpC-GFP constructs were stained with anti-Ag85A monoclonal antibodies (mAbs) and Alexa Fluor 568-conjugated anti-mouse IgG antibody, respectively. Following staining with mAbs 1C6 and 3B8, only HEK293T cells transfected with pcDNA3.1-ftbpA-GFP exhibited yellow fluorescence (A,D). However, HEK293T cells transfected with pcDNA3.1-ftbpB-GFP and/or pcDNA3.1-ftbpC-GFP also exhibited yellow fluorescence following staining with mAbs 2E6, 2F2, and 3D9 (B,C,E). The control group was HEK293T cells stained with SP2/0 ascites (F).

FIGURE 4 | Detection of Ag85A protein in BCG and rBCG:Ag85A. BCG and rBCG:Ag85A were detected using indirect ELISA and Western blot. All anti-Ag85A monoclonal antibodies (mAbs) were able to react with endogenous Ag85A protein in BCG and rBCG:Ag85A group (A). All of the mAbs were able to recognize endogenous Ag85A protein in rBCG:Ag85A (B) lane 1 and BCG (B) lane 2. The control group was SP2/0 ascites control. Data depicted are the mean values ± SEM. Statistical significance was determined by a Student's t-test (*P < 0.05).
antibody HYT 27 only reacts strongly with *M. tuberculosis* Ag85C protein. The rabbit polyclonal antibody against *M. tuberculosis* Ag85B is only specific for the Ag85B protein.

Here, we used rGST-Ag85A protein as an immune antigen and rHis-Ag85A protein as a detective antigen. A total of five mAbs were established, and named as 1C6, 2E6, 2F2, 3B8, and 3D9. All nine mAbs used in this study were determined to be of the IgG1 isotype. Analysis of the generated mAbs showed that both hybridoma supernatant and ascites had a high titer. In addition, we show through Western blot analysis that all of the mAbs generated in this study are able to react with recombinant Ag85A protein. All the mAbs did not react with selected mycobacteria protein, suggesting these mAbs are specific to Ag85A protein.

*Mycobacterium tuberculosis* Ag85A, Ag85B, and Ag85C are highly homologous on the DNA and amino acid level (6). In order to evaluate the cross-reactivity of anti-Ag85A mAbs with the Ag85 complex, the HEK293T cells transfected with pcDNA3.1-recipient Ag85A, Ag85B, and Ag85C protein. It may be beneficial to the wide employment of anti-Ag85A mAbs.

In previous works, we developed many mAbs using recombinant protein expressed in *E. coli*. All of these mAbs may have good reactivity against recombinant proteins but may not be reactive against the natural proteins (30). As a result, we identified the reactivity of anti-Ag85A mAbs against BCG. The indirect ELISA and Western blot analysis showed that all of the generated mAbs are able to react with endogenous Ag85A protein in BCG and rBCG:Ag85A. Currently, several serological tests with promising accuracy have recently emerged, many ELISA technology has been intensively established for the detection of serum antibodies of bovine TB (31–34). In this research, a cELISA based on mAb 3B8 was developed, the analyses of clinic serum samples of bovine TB (31–34). In this research, a cELISA based on mAb 3B8 was developed, the analyses of clinic serum samples of bovine TB (31–34). In this research, a cELISA based on mAb 3B8 was developed, the analyses of clinic serum samples of bovine TB (31–34). In this research, a cELISA based on mAb 3B8 was developed, the analyses of clinic serum samples of bovine TB (31–34). In this research, a cELISA based on mAb 3B8 was developed, the analyses of clinic serum samples of bovine TB (31–34). In this research, a cELISA based on mAb 3B8 was developed, the analyses of clinic serum samples of bovine TB (31–34).

**REFERENCES**

1. WHO. Global tuberculosis report 2016. *World Health Organisation Report*. (2016). Available from: http://www.who.int/tb/publications/global_report/en/
2. Yates TA, Khan PJ, Knight GM, Taylor JG, McHugh TD, Lipman M, et al. The transmission of *Mycobacterium tuberculosis* in high burden settings. *Lancet Infect Dis* (2016) 16:227–38. doi:10.1016/S1473-3099(15)00499-5
3. Rappuoli R. Changing route: aerosol vaccine against tuberculosis. *Lancet Infect Dis* (2014) 14:901–2. doi:10.1016/S1473-3099(14)70886-2
4. Wiker HG, Harboe M. The antigen 85 complex: a major secretion product of *M. bovis*-elicited pathology and biological function of the Ag85 complex; in addition, these antibodies could act as important materials for the development of a diagnostic method for TB, as well as identification of novel drug candidates for the treatment of this infectious disease.

**AUTHOR CONTRIBUTIONS**

ZX, XC, and XJ designed the experiments. ZX, TH, AX, XL, ZL, JM, JH, and CM performed the experiments and analyzed the data. YY, XC, and XJ contributed reagents/materials/analysis tools. ZX, XC, and XJ wrote and revised the paper.

**FUNDING**

This work was supported in part by the National Key Research and Development Program of China (2017YFD0500300), the National Natural Science Foundation of China (31602031), the Science and Technology Program of Jiangsu (BE2015343, BK20160466, 16KJB230003), and the Qinglan Project and Priority Academic Development Program of Jiangsu Higher Education Institutions (PADP).
Xu et al.
mAbs against Ag85A

11. Elamin AA, Stehr M, Oehlimann W, Singh M. The mycolyltransferase 85A, a putative drug target of Mycobacterium tuberculosis: development of a novel assay and quantification of glycolipid-status of the mycobacterial cell wall. *J Microbiol Methods* (2009) 79:358–63. doi:10.1016/j.mimet.2009.10.010

12. Rosseels V, Marche S, Roupie V, Govaerts M, Godfroid J, Walravens K, et al. Members of the 30- to 32-kilodalton mycolyl transferase family (Ag85) from culture filtrate of *Mycobacterium avium* subsp. paratuberculosis are immuno-nodominant Th1-type antigens recognized early upon infection in mice and cattle. *Infect Immun* (2006) 74:202–12. doi:10.1128/JAI.74.1.202-212.2006

13. Macedo GC, Bozzi A, Weinreich HR, Bafica A, Teixeira HC, Oliveira SC. Human T cell and antibody-mediated responses to the *Mycobacterium tuberculosis* recombinant Ag85A, Ag85B, and ESAT-6 antigens. *Clin Dev Immunol* (2011) 2011:351573. doi:10.1155/2011/351573

14. Metcalfe HJ, Steinbach S, Jones GJ, Connelley T, Morrison WT, Vordermeier M, et al. Protection associated with a TB vaccine is linked to increased frequency of Ag85A-specific CD4(+) T cells but no increase in avidity for Ag85A. *Vaccine* (2016) 34:4520–25. doi:10.1016/j.vaccine.2016.07.055

15. Harris SA, Meyer J, Satti I, Marsay L, Poulton ID, Tanner R, et al. Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination. *J Infect Dis* (2014) 209:1259–68. doi:10.1093/infdis/jiu647

16. Jeyanathan M, Damjanovic D, Yao Y, Bramson J, Smaill F, Xing Z. Induction of vesiculogenesis and immunomodulation in the lung. *J Immunol* (2014) 192:1651–60. doi:10.4049/jimmunol.1301743

17. Kashyap RS, Rajan AN, Ramteke SS, Agrawal VS, Kelkar SS, Purohit HJ, et al. Diagnosis of tuberculosis in an Indian population by an indirect ELISA protocol based on detection of antigen 85 complex: a prospective cohort study. *BMC Infect Dis* (2007) 7:74. doi:10.1186/1471-2334-7-74

18. Drowart A, De Bruyn J, Huygen K, Damiani G, Godfrey HP, Stelandre M, et al. Isoelectrofocusing characterization of protein antigens present in mycobacterial culture filtrates and recognized by monoclonal antibodies directed against the *Mycobacterium bovis* BCG antigen 85 complex. *Scand J Immunol* (1992) 36:697–702. doi:10.1111/j.1365-3083.1992.tb03130.x

19. Ferrara F, Naranjo LA, Kumar S, Gaiotto T, Morrison WT, Vordermeier M, et al. Using phage and yeast display to select hundreds of monoclonal antibodies: application to antigen 85, a tuberculosis biomarker. *PLoS One* (2012) 7:e49535. doi:10.1371/journal.pone.0049535

20. Phunpae P, Chanwong S, Tarapitawatana C, Apatrimatekul N, Makeudom N, Kaisinerk W. Rapid diagnosis of tuberculosis by identification of antigen 85 in mycobacterial culture system. *Diagn Microbiol Infect Dis* (2014) 78:242–8. doi:10.1016/j.dmiid.2013.11.028

21. Solans L, Gonzalo-Aesenio J, Sala C, Benjak A, Uplekar S, Rougemont J, et al. The PhoP-dependent ncRNA Mcr7 modulates the TAT secretion system in *Mycobacterium tuberculosis*. *PLoS Pathog* (2014) 10:e1004183. doi:10.1371/journal.ppat.1004183

22. Rengarajan J, Murphy E, Park A, Krone CL, Hett EC, Bloom BR, et al. *Mycobacterium tuberculosis* Rs2224c modulates innate immune responses. *Proc Natl Acad Sci U S A* (2008) 105:265–9. doi:10.1073/pnas.0710601010

23. Torab-Pariz A, Vrisekoop N, Kastenmuller W, Gerner MY, Egen JG, Germain RN. Pathogen-related differences in the abundance of presented antigen are reflected in CD4+ T cell dynamic behavior and effector function in the lung. *J Immunol* (2014) 192:1651–60. doi:10.4049/jimmunol.1301743

24. Rath P, Huang C, Wang T, Wang T, Li H, Prados-Rossales R, et al. Genetic regulation of vesiculogenesis and immunomodulation in *Mycobacterium tuberculosis*. *Proc Natl Acad Sci U S A* (2013) 110:E4790–7. doi:10.1073/pnas.1320118110

25. Chen X, Ou Z, Xie XL, Xu ZZ, Jiao XA. Preparation of monoclonal antibodies against *Mycobacterium tuberculosis* TB10.4 antigen. *Monoclon Antib Immunodiotag Immunother* (2014) 33:444–7. doi:10.1089/mab.2014.0039

26. Xu ZZ, Chen X, Hu T, Meng C, Wang XB, Rao Y, et al. Evaluation of immunogenicity and protective efficacy elicited by *Mycobacterium bovis* BCG overexpressing Ag85A protein against *Mycobacterium tuberculosis* aerosol infection. *Front Cell Infect Microbiol* (2016) 6:3. doi:10.3389/fcimb.2016.00003

27. Daffe M. The mycobacterial antigens 85 complex – from structure to function and beyond. *Trends Microbiol* (2000) 8:438–40. doi:10.1016/S0966-842X(00)01844-8

28. Denis O, Tanghe A, Palliet K, Jurion F, van den Berg TP, Vanonckelen A, et al. Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by *Mycobacterium tuberculosis* H37Rv infection. *Infect Immun* (1998) 66:1527–33.

29. Kamath AT, Rochat AF, Valenti MP, Agger EM, Lingnau K, Andersen P, et al. Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant. *PLoS One* (2008) 3:e3683. doi:10.1371/journal.pone.0003683

30. Xu Z, Shan F, Shan F, Meng C, Zhou X, Zhang X, et al. Generation and application of a 293 cell line stably expressing bovine interferon-gamma. *Protein Expr Purif* (2014) 99:131–7. doi:10.1016/j.pep.2014.04.012

31. Casal C, Infantes JA, Risalde MA, Diez-Guerrier A, Dominguez M, Moreno I, et al. Antibody detection tests improve the sensitivity of tuberculosis diagnosis in cattle. *Res Vet Sci* (2017) 112:214–21. doi:10.1016/j.rvsc.2017.05.012

32. Liu S, Guo S, Wang C, Shao M, Zhang X, Guo Y, et al. A novel fusion protein-based indirect enzyme-linked immunosorbant assay for the detection of bovine tuberculosis. *Tuberculosis* (Edinb) (2007) 87:212–7. doi:10.1016/j.tube.2006.07.007

33. Green LR, Jones CC, Sherwood AL, Garkavi IV, Cangelosi GA, Thacker TC, et al. Single-antigen serological testing for bovine tuberculosis. *Clin Vaccine Immunol* (2009) 16:1309–13. doi:10.1128/CVI.00028-09

34. Waters WR, Buddle BM, Vordermeier HM, Gormley E, Palmer MV, Thacker TC, et al. Development and evaluation of an enzyme-linked immunosorbant assay for use in the detection of bovine tuberculosis in cattle. *Clin Vaccine Immunol* (2011) 18:1882–8. doi:10.1128/CVI.05343-11

35. Waters WR, Whelan AO, Lyashchenko KP, Greenwald R, Palmer MV, Harris BN, et al. Immune responses in cattle inoculated with *Mycobacterium bovis*, *Mycobacterium tuberculosis*, or *Mycobacterium kansasii*. *Clin Vaccine Immunol* (2010) 17:247–52. doi:10.1128/CVI.00442-09

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Xu, Hu, Xia, Li, Liu, Min, He, Meng, Yin, Chen and Jiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.